Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review

Table 2 Baseline patient characteristics

	RTOG-85-31[9, 10]		Granfors et al.[11, 12]		EST-3886[13–15]		EPC program[16, 17]
	early AST (n = 98)	deferred AST (n = 75)	early AST (n = 19)	deferred AST (n = 20)	early AST (n = 47)	deferred AST (n = 51)	early/deferred AST (n = 150) (a)
Age (years)	median 64	median 66	mean 68.8		median 65.1	median 66.6	mean 64.6
Age (years)	(range 44–79)	(range 50–77)	(range 49.2-75.3)		(range 52–75)	(range 45–78)	(range 52–84)
Gleason score (n) not known	10	10	-	-	3	6	5
2-4	-	-	-	-	-	-	22
5-6	-	-	-	-	-	-	60
3-6	-	-	-	-	9	11	-
2-7	55	43	-	-	-	-	-
7	-	-	-	-	26	29	-
7-10	-	-	-	-	-	-	63
8-10	33	22	-	-	9	5	-
Grade (n) G1	-	-	3	4	-	-	-
G2	-	-	13	12	-	-	-
G3	-	-	4	3	-	-	-
T stage (n) T1	3	6	2	2	-	-	43
T2	68	53	13	11	-	-	98
T3	27	16	4	6	-	-	9
T4	-	-	1	0	-	-	0
Positive surgical margins (n)	-	-	-	-	32	31	-
Positive seminal vesicle (n)	-	-	-	-	27	32	-
Nodal status (n) assessed	-	-	-	-	median 11	median 14	-
Nodal status (n) assessed	-	-	-	-	(range 3–36)	(range 2–39)	-
positive	-	-	-	-	median 2	median 2	-
					(range 1–19)	(range 1–20)

(a). Authors reported data for baseline patient characteristics only for the group of patients with node-positive prostate cancer but not for patients randomized to early or deferred androgen suppression therapy.

ISSN: 1471-2407